Skip to main content
. Author manuscript; available in PMC: 2013 Jul 6.
Published in final edited form as: Invest New Drugs. 2012 Feb 14;30(6):2364–2370. doi: 10.1007/s10637-012-9800-3

Table 2.

Treatment-related adverse events

Adverse event Grade 1–2
No. of patients (%)
Grade 3
No. of patients (%)
Grade 4
No. of patients (%)
Fatigue 7 (39) 0 1 (6)
Nausea 7 (39) 0 0
Anemia 3 (17) 1 (6) 0
Vomiting 4 (22) 0 0
Alopecia 3 (17) 0 0
Mucosal inflammation 1 (6) 2 (11) 0
Neutropenia 1 (6) 2 (11) 0
Diarrhea 1 (6) 1 (6) 0
Muscular weakness 1 (6) 0 1 (6)
Thrombocytopenia 1 (6) 0 1 (6)
Dysgeusia 2 (11) 0 0
Dysphagia 0 2 (11) 0
Neuropathy peripheral 2 (11) 0 0
Stomatitis 2 (11) 0 0
Escherichia infection 0 1 (6) 0
Febrile neutropenia 0 0 1 (6)
Fungal infection 0 1 (6) 0
Leukopenia 0 0 1 (6)
Neutropenic sepsis 0 0 1 (6)
Pneumonia, aspiration 0 0 1 (6)